| A10 | antineoplaston A10 |
| A6 | urokinase-derived peptide A6 |
| AAFC | flurocitabine |
| AAP | alanine aminopeptidase |
| AAT | alpha-1-proteinase inhibitor human |
| AbGn-7 | monoclonal antibody AbGn-7 |
| ABI-007 | Abraxane; nanoparticle paclitaxel; paclitaxel albumin-stabilized nanoparticle formulation; protein-bound paclitaxel |
| ABPP | bropirimine |
| ABT-263 | navitoclax |
| ABT-806i | indium In 111 anti-EGFR monoclonal antibody ABT-806 |
| ABT-869 | multitargeted receptor tyrosine kinase inhibitor ABT-869 |
| ABT-888 | PARP-1 inhibitor ABT-888; veliparib |
| ABVD | ABVD regimen |
| ABVE | ABVE regimen; DBVE regimen |
| ABVE-PC | ABVE-PC regimen; DBVE-PC regimen |
| ABX-EGF | panitumumab; Vectibix |
| AC | AC regimen |
| ACC | amorphous calcium carbonate |
| ACCS | amnion-derived cellular cytokine solution |
| ACDM | acellular cadaveric dermal matrix |
| ACF | aberrant crypt foci |
| ACM | aclarubicin |
| ACMP | acetaminophen |
| ACN53 | rAd/p53; recombinant adenovirus-p53 |
| ACNU | nimustine |
| ACP | cycloleucine |
| AC-T | AC-T regimen; AC-Taxol regimen |
| ACTH | adrenocorticotropic hormone; corticotropin |
| ACTHoma | adrenocorticotropic-secreting tumor |
| AC-T-T | AC-T-T regimen; AC-TH regimen; sequential AC/Taxol-Trastuzumab regimen |
| ACV | acyclovir |
| Ad5/3-D24-GMCSF | GM-CSF-encoding oncolytic adenovirus CGTG-102 |
| Ad5-CMV-NIS | recombinant type 5 adenovirus carrying the human NIS gene linked to the CMV promotor |
| Ad5CMV-p53 | contusugene ladenovec |
| Ad5-TNFa | golnerminogene pradenovec |
| ADA-SCID | adenosine deaminase-deficient severe combined immunodeficiency |
| ADC | antibody-drug conjugate; therapeutic autologous dendritic cells |
| ADC AGS-16C3F | anti-ENPP3 antibody-drug conjugate AGS-16C3F |
| ADC IMMU-130 | labetuzumab-SN-38 immunoconjugate IMMU-130 |
| ADC SGN-19A | denintuzumab mafodotin |
| ADCC | antibody-dependent cell-mediated cytotoxicity; antibody-dependent cellular cytotoxicity |
| Ad-CD40L | adenovirus 5-CD40 ligand |
| ADE | ADE regimen |
| ADH | atypical ductal breast hyperplasia; atypical ductal hyperplasia |
| AdhAQP1 | adenovirus encoding human aquaporin-1 |
| AdHer2/DC | adenovirus HER2-transduced autologous dendritic cell vaccine |
| Ad.hIL-12 | adenovirus-mediated human interleukin-12 |
| Ad-IFNg | interferon-gamma-expressing adenovirus vaccine ASN-002 |
| Ad-ISF35 | Ad-CD40L ISF35; Ad-CD154 ISF35 |
| ADL | activities of daily living |
| Ad/L523S | recombinant adenovirus-L523S vaccine |
| ADM | doxorubicin hydrochloride |
| Ad-MAGE-A3 | MAGE-A3-expressing adenovirus type5 vaccine |
| A-dmDT390-bisFv(UCHT1) | anti-CD3 immunotoxin A-dmDT390-bisFv(UCHT1) |
| ADRC | adipose-derived regenerative cells |
| Ad-rhENDO | adenovirus encoding recombinant human endostatin |
| Ad-RTS-hIL-12 | adaoviral-rheoswitch therapeutic system-human interleukin 12 |
| Ad-RTS-IL-12 plus AL | adenovirus-mediated human interleukin-12 INXN-2001 plus activator ligand INXN-1001 |
| ADV | adenovirus vector |
| AdVhAFP | alpha fetoprotein adenoviral vector vaccine |
| ADV-tk | aglatimagene besadenovec |
| AEO | anhydrous enol-oxaloacetate |
| AFAP | attenuated familial adenomatous polyposis |
| AFLD | alcoholic fatty liver disease |
| AFP | alpha-fetoprotein |
| AFP-C332 T cells | TCR-specific, alpha fetoprotein-enhanced autologous T lymphocytes |
| AG | alanylglutamine |
| AG014699 | PARP-1 inhibitor AG014699; Rubraca; rucaparib camsylate |
| AG3340 | prinomastat |
| AG337 | nolatrexed; Thymitaq |
| a-GalCer | alpha galactosylceramide |
| AGC | atypical glandular cells |
| AGUS | atypical glandular cells of uncertain significance; atypical glandular cells of undetermined significance |
| AHA | alpha hydroxyl acid; fruit acid |
| AI | artificial intelligence |
| AIDS | acquired immunodeficiency syndrome |
| AIE | AIE regimen |
| AIJP | Arnebia Indigo Jade Pearl topical cream |
| AIM2(-1)/HT001(-1)/TAF1B(-1) FSP vaccine | AIM2(-1)/HT001(-1)/TAF1B(-1) frameshift peptide vaccine |
| AIS | adenocarcinoma in situ |
| AL | therapeutic autologous lymphocytes |
| ALCAR | acetyl-L-carnitine hydrochloride |
| ALCL | anaplastic large cell lymphoma |
| ALH | atypical lobular breast hyperplasia; atypical lobular hyperplasia |
| ALL | acute lymphoblastic leukemia; acute lymphocytic leukemia |
| allogeneic adults MSCs | remestemcel-L |
| allogeneic CMV-specific CTLs | allogeneic cytomegalovirus-specific cytotoxic T lymphocytes |
| allogeneic HPV-CTLs | allogeneic HPV-specific cytotoxic T lymphocytes |
| allogeneic NK cell line MG4101 | allogeneic natural killer cell line MG4101 |
| ALLOLYMPH | therapeutic allogeneic lymphocytes |
| ALLOTCV | allogeneic tumor cell vaccine |
| alphaDC1 | alpha-type-1 polarized dendritic cells |
| ALTENS | acupuncture-like transcutaneous electrical nerve stimulation |
| ALTN HCl | catequentinib hydrochloride |
| ALVAC-CEA | ALVAC-CEA vaccine |
| AMD | age-related macular degeneration |
| AMH | anti-Mullerian hormone |
| aMIL | activated marrow infiltrating lymphocytes |
| AML | acute myelogenous leukemia; acute myeloid leukemia; acute nonlymphocytic leukemia |
| AML-MRC | acute myeloid leukemia with myelodysplasia-related changes |
| ammonium TM | tiomolibdate diammonium |
| AMOX | amoxicillin |
| AMP | absorbable modified polymer hemostatic powder |
| AMSA | amsacrine |
| ANAN | nilutamide |
| ANC | absolute neutrophil count |
| ANH | artificial nutrition and hydration |
| ANLL | acute myelogenous leukemia; acute myeloid leukemia; acute nonlymphocytic leukemia |
| ANS | autonomic nervous system; involuntary nervous system |
| anti c-KIT ADC LOP628 | anti c-KIT antibody-drug conjugate LOP628 |
| anti-α5β1 integrin MOAB | volociximab |
| anti-ANG2 MoAb MEDI-3617 | anti-ANG2 monoclonal antibody MEDI-3617 |
| anti-B4-BR | anti-B4 blocked ricin immunotoxin |
| anti-C4.4a ADC BAY1129980 | anti-C4.4a antibody-drug conjugate BAY1129980 |
| anti-CD3 x CD20Bi-armed ATC | anti-CD3 x anti-CD20 bispecific antibody-armed activated T cells |
| anti-CD70 ADC MDX-1203 | anti-CD70 antibody-drug conjugate MDX-1203 |
| anti-CTGF hmAb FG-3019 | pamrevlumab |
| anti-EGFR MoAb ABT-806 | anti-EGFR monoclonal antibody ABT-806 |
| anti-EphA3 mAb KB004 | anti-EphA3 monoclonal antibody KB004 |
| anti-huGITR MoAb TRX518 | anti-human GITR monoclonal antibody TRX518 |
| anti-OX40 MoAb | anti-OX40 monoclonal antibody |
| anti-P3 Ab idiotype mAB1E10 | racotumomab |
| anti-PSMA-MMAE-ADC | anti-PSMA monoclonal antibody-MMAE conjugate |
| anti-RAAG12 MOAB | monoclonal antibody RAV12 |
| ANV | anticipatory nausea and vomiting |
| AP23573 | ridaforolimus |
| AP24534 HCl | ponatinib hydrochloride |
| APAETP | amifostine |
| APC | antigen-presenting cell |
| APGA | aminopterin |
| API | active pharmaceutical ingredient; drug substance; pharmacologic substance |
| APL | acute promyelocytic leukemia |
| APN | advanced practice nurse; nurse practitioner |
| Apo-2L | TNF-related apoptosis-inducing ligand; tumor necrosis factor-related apoptosis-inducing ligand |
| AR | androgen receptor |
| AR antagonist ARN-509 | apalutamide |
| ARA-A | vidarabine |
| ARA-AC | fazarabine |
| ARA-C | cytarabine |
| ARA-C/DNR/VP-16 | ADE regimen |
| ARMD | age-related macular degeneration |
| ARMS | alveolar rhabdomyosarcoma |
| ART | assisted reproductive technology; artesunate |
| AS2-1 | antineoplaston AS2-1 |
| ASA | aspirin |
| ASC-H | atypical squamous cells, cannot exclude a high-grade lesion |
| ASC-US | atypical squamous cells of undetermined significance |
| ASCUS | atypical squamous cells of undetermined significance |
| ASM | aggressive systemic mastocytosis |
| ASPS | alveolar soft part sarcoma |
| ASV | asunaprevir |
| At 211 MAb BC8-B10 | astatine At 211 anti-CD45 monoclonal antibody BC8-B10 |
| AT7519M | CDK inhibitor AT7519M |
| AT9283 | Aurora kinase inhibitor AT9283 |
| ATCV | autologous tumor cell vaccine |
| A-TD | aminothiadiazole |
| α-TEA | Alpha-tocopheryloxyacetic Acid |
| ATG | anti-thymocyte globulin |
| ATIII | therapeutic human antithrombin-III |
| ATLL | adult T-cell leukemia/lymphoma |
| ATN-224 | SOD1 inhibitor ATN-224 |
| ATO | arsenic trioxide |
| ATP | adenosine triphosphate |
| ATRA | all-trans retinoic acid; tretinoin; vitamin A acid |
| AT/RT | atypical teratoid/rhabdoid tumor |
| aTTP | acquired thrombotic thrombocytopenic purpura |
| ATT/RHT | atypical teratoid/rhabdoid tumor |
| autologous DC1-CTL | type-1 polarized dendritic cell-induced antigen-specific autologous cytotoxic T lymphocytes |
| autologous HPV-CTLs | autologous HPV-specific cytotoxic T lymphocytes |
| autologous iC9-CARCD19 T cells | autologous iCASP9-CD19-expressing T lymphocytes |
| autologous IKDC | autologous interferon-producing killer dendritic cells |
| autologous RCC tumor lysate-DC vaccine | Autologous Renal Cell Carcinoma Tumor Lysate-Pulsed Dendritic Cell Vaccine |
| autologous TAPA-pulsed DC vaccine KiroVAX | autologous tumor-associated peptide antigen-pulsed dendritic cell vaccine |
| AVLB | anhydrovinblastine |
| AZ | azimexon |
| Aza-TdC | 5-Aza-4'-thio-2'-deoxycytidine |
| AZD2171 | cediranib maleate; Recentin |
| AZD2281 | Lynparza; olaparib; PARP inhibitor AZD2281 |
| AZD6244 | Koselugo; MEK inhibitor AZD6244; selumetinib sulfate |
| AZQ | diaziquone |
| AZS | azaserine |
| AZT | zidovudine |
| azurin:50-77 CPP p28 | azurin-derived cell-penetrating peptide p28 |